Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...

Centrally Acting Muscle Relaxants: Therapeutic Uses

Centrally Acting Muscle Relaxants: Therapeutic Uses

Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...

Peripherally and Centrally Acting Muscle Relaxants: A Comparison

Peripherally and Centrally Acting Muscle Relaxants: A Comparison

Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Therapeutic advances in fibromyalgia: one year in review 2026.

Clinical and experimental rheumatology·2026

Same author

Pathogenetic and clinical aspects of fibromyalgia: one year in review 2026.

Clinical and experimental rheumatology·2026

Same author

War, trauma and pain: an invisible and enduring burden.

Clinical and experimental rheumatology·2026

Same author

Invisible pain, visible change: the impact of multidisciplinary treatment on women with fibromyalgia.

Clinical and experimental rheumatology·2026

Same author

Via Dolorosa: impact of nociplastic pain on hospitalisation outcomes. A retrospective cohort study.

Clinical and experimental rheumatology·2026

Same author

"You Could Have Prevented It!": attributions of responsibility toward COVID-19 unvaccinated vs. vaccinated individuals.

BMC public health·2026

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

Published on: January 5, 2024

Emerging therapies for fibromyalgia.

Jacob N Ablin¹, Dan Buskila

¹Tel Aviv Sourasky Medical Center, Rheumatology Institute, Tel Aviv, Israel.

Expert Opinion on Emerging Drugs

|March 7, 2008

Summary

Fibromyalgia syndrome (FMS) treatment is evolving. The FDA approval of pregabalin marks a new era for developing more specific and effective medications for this chronic pain disorder.

Area of Science:

Neurology
Pharmacology
Pain Management

Background:

Fibromyalgia syndrome (FMS) is a prevalent chronic disorder characterized by widespread pain, fatigue, and altered central pain processing.
FMS significantly impacts quality of life, vocational capacity, and healthcare utilization.
The condition follows a chronic, non-progressive course.

Purpose of the Study:

To review current and emerging trends in the treatment of fibromyalgia syndrome.
To highlight advancements in pharmacological interventions for FMS.

Main Methods:

A comprehensive literature search was conducted.
Included published studies, abstract presentations, and industry-provided data.

Main Results:

More Related Videos

Home-Based Transcranial Direct Current Stimulation Device Development: An Updated Protocol Used at Home in Healthy Subjects and Fibromyalgia Patients

Home-Based Transcranial Direct Current Stimulation Device Development: An Updated Protocol Used at Home in Healthy Subjects and Fibromyalgia Patients

Published on: July 14, 2018

Related Experiment Videos

Last Updated: Jul 6, 2026

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

Published on: January 5, 2024

Home-Based Transcranial Direct Current Stimulation Device Development: An Updated Protocol Used at Home in Healthy Subjects and Fibromyalgia Patients

Home-Based Transcranial Direct Current Stimulation Device Development: An Updated Protocol Used at Home in Healthy Subjects and Fibromyalgia Patients

Published on: July 14, 2018

The recent FDA approval of pregabalin represents a significant development in FMS pharmacotherapy.
Pregabalin is the first specific medication approved for FMS.

Conclusions:

The approval of pregabalin may signify a new era in FMS treatment development.
Future research will likely focus on medications with enhanced specificity and efficacy for fibromyalgia syndrome.